|
Acanthosis
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Adrenoleukodystrophy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Transcription of MIR122 is inhibited by GRHL2, which is increased in livers of mice and patients with ALD.
|
28987423 |
2018 |
|
ANONYCHIA
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.010 |
Biomarker
|
disease |
BEFREE |
GRHL2 regulates epithelial plasticity along with stemness in PDAC, both of which are crucial for metastasis, implicating the possibility of GRHL2 as a therapeutic target for PDAC liver metastasis.
|
28960866 |
2017 |
|
Bacteremia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
These data indicate that <i>Pg</i> bacteria may enhance paracellular penetration through oral mucosa in part by targeting the expression of GRHL2 in the oral epithelial cells, which then impairs the epithelial barrier by inhibition of junction protein expression, resulting in increased alveolar tissue destruction and systemic bacteremia.
|
31340691 |
2019 |
|
Breast Carcinoma
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Large clinical datasets reveal that expression of Grhl2 is significantly associated with poor relapse free survival and increased risk of metastasis in breast cancer patients.
|
23284647 |
2012 |
|
Breast Carcinoma
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
In clinical cohorts, loss of DLC1 and gain of GRHL2 expression are associated with ER<sup>+</sup> breast cancer and are independently predictive for worse survival.
|
31110002 |
2019 |
|
Breast Carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
Using cellular and mouse models of endocrine therapy-sensitive and endocrine therapy-resistant breast cancer, together with contemporary discovery platforms, we identified a targetable pathway that is composed of the transcription factors FOXA1 and GRHL2, a coregulated target gene, the membrane receptor LYPD3, and the LYPD3 ligand, AGR2.
|
31644911 |
2019 |
|
Breast Carcinoma
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Correction to: VULCAN integrates ChIP-seq with patient-derived co-expression networks to identify GRHL2 as a key co-regulator of ERa at enhancers in breast cancer.
|
31200751 |
2019 |
|
Breast Carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
This GSP is independent of most traditional prognostic indicators, and is only significantly associated with the histological grade of breast cancer (p = 0.0017), a GRHL2-associated clinical character (p = 6.8e-6, Spearman correlation), suggesting that this GSP is reflective of GRHL2-mediated events.
|
23441166 |
2013 |
|
Breast Carcinoma
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Supporting the relevance of EDD1 and GRHL2 as therapeutic candidates to engage apoptosis in cancer cells, silencing the expression of either gene sensitizes 8q22-amplified breast cancer cell lines to death receptor induced apoptosis.
|
21949371 |
2011 |
|
Breast Carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
A pathophysiological relevance of GRHL2 in breast cancer metastasis is further demonstrated by our finding of a statistically significant association between loss of GRHL2 expression in primary breast cancers and lymph node metastasis.
|
23814079 |
2013 |
|
Breast Carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
VULCAN analysis of estrogen receptor activation in breast cancer highlights the key components of the estrogen receptor complex alongside a novel interaction with GRHL2.
|
31084623 |
2019 |
|
Breast Carcinoma
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Further, we show that high GRHL2 expression is highly correlated with worse relapse-free survival in all four subtypes of breast cancer.
|
28266048 |
2017 |
|
Carcinogenesis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
In this study, we investigated the role of GRHL2 in oral carcinogenesis and the underlying mechanism.
|
26933170 |
2016 |
|
Carcinogenesis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
We thus demonstrate a crucial role of GRHL2 in breast carcinogenesis.
|
23814079 |
2013 |
|
Carcinogenesis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Here, we report the role of GRHL2 in oral carcinogenesis in vivo using a novel Grhl2 knockout (KO) mouse model and the underlying mechanism involving its functional interaction with TGF-β signaling.
|
29735981 |
2018 |
|
Carcinogenesis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
In addition to its important role in development, grainyhead-like 2 is implicated in carcinogenesis as well.
|
28459369 |
2017 |
|
Carcinogenesis
|
0.050 |
AlteredExpression
|
phenotype |
BEFREE |
In conclusion, a loss or strong reduction in GRHL2 expression appears to be a characteristic of cervical cancer, suggesting that GRHL2 down-regulation is a necessary step during cervical carcinogenesis.
|
25550776 |
2014 |
|
Carcinoma of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
By using a series of silencing and overexpression studies, we show that EDD1 and GRHL2 suppress death-receptor expression, and that EDD1 expression is elevated in breast, pancreas, and lung cancer cell lines resistant to death receptor-mediated apoptosis.
|
21949371 |
2011 |
|
Carcinoma, Ovarian Epithelial
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, our data are indicative for a strong oncogenic potential of the GRHL2 gene in EOC progression and support recent findings on the role of GRHL2 as one of the major phenotypic stability factors (PSFs) that stabilize the highly aggressive/metastatic hybrid epithelial/mesenchymal (E/M) phenotype of cancer cells.
|
28278050 |
2017 |
|
cervical cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, further studies are needed to delineate the role of GRHL2 in cervical cancer and during malignant progression.
|
25550776 |
2014 |
|
Cervix carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, further studies are needed to delineate the role of GRHL2 in cervical cancer and during malignant progression.
|
25550776 |
2014 |
|
Colorectal Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
For knockdown of GRHL2, two small interfere RNAs (siRNAs) targeting GRHL2 or control siRNA was transfected into CRC cell lines (HCT116 and HT29).
|
30917932 |
2019 |
|
Colorectal Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
CRC cells were injected into mice tail vein to verify the impact of GRHL2 on CRC metastasis.
|
31063022 |
2019 |